Should the LIFE Trial Assess Improvement in Ejection Fraction as a Primary Endpoint?

Authors :: Steny Simon
Amit K J Mandal
Constantinos G. Missouris
Adam Ioannou
Sofia Metaxa
Source :: JACC: Heart Failure. 8:959-960
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.
Abstract: Mann et al. ([1][1]) recently published the protocol for the LIFE (LCZ696 in Hospitalized Advanced Heart Failure) study. In this multicenter prospective trial, the investigators aimed to assess whether 24 weeks of sacubitril/valsartan therapy led to a significant reduction in N-terminal pro−B

Subjects :: medicine.medical_specialty
Ejection fraction
business.industry
030204 cardiovascular system & hematology
medicine.disease
Sacubitril
03 medical and health sciences
0302 clinical medicine
Valsartan
Prospective trial
Heart failure
Internal medicine
medicine
Clinical endpoint
030212 general & internal medicine
Cardiology and Cardiovascular Medicine
business
medicine.drug

Full Text Access

Tools